Francesco De Rubertis, Alys Pharmaceuticals chairman
With first drug now in the clinic, Alys eyes megaround for rest of pipeline
Alys Pharmaceuticals is on the hunt for a large financing to carry forward its pipeline — an amalgamation of six Medicxi startups — following the
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
